John Miller
Corporate Officer/Principal at JAZZ PHARMACEUTICALS PLC
John Miller active positions
| Companies | Position | Start | End |
|---|---|---|---|
| JAZZ PHARMACEUTICALS PLC | Corporate Officer/Principal | 2015-01-31 | - |
Career history of John Miller
Former positions of John Miller
| Companies | Position | Start | End |
|---|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2012-01-31 | 2012-07-31 |
Enobia Pharma, Inc.
 Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Corporate Officer/Principal | 2011-01-31 | 2012-01-31 |
Training of John Miller
| University of Mississippi | Undergraduate Degree |
| Questrom School of Business | Masters Business Admin |
Statistics
International
| United States | 4 |
| Ireland | 2 |
| Canada | 2 |
Operational
| Corporate Officer/Principal | 3 |
| Undergraduate Degree | 1 |
| Masters Business Admin | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| JAZZ PHARMACEUTICALS PLC | Health Technology |
| Private companies | 2 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Health Technology |
- Stock Market
- Insiders
- John Miller
- Experience
